文献速递病毒性肝炎艾滋病与性传播感染

慢性乙型或丙型肝炎病毒感染患者(伴或不伴HIV合并感染)的DNA甲基化与免疫细胞标志物显示加速衰老

DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic Hepatitis B Virus or Hepatitis C Virus, with or without Human Immunodeficienct Virus Co-infection.
PubMed 文献 · Clin Infect Dis · 2021-01-01

研究探讨慢性HBV或HCV感染患者(伴或不伴HIV合并感染)的表观遗传年龄加速及外周血DNA甲基化与免疫细胞标志物的关联。结果显示慢性HBV患者表观遗传年龄显著高于实际年龄,HCV患者年龄加速与肝纤维化或HIV合并感染相关,免疫标志物定义的年龄加速与DNA甲基化一致,核苷治疗1年可 modestly 减少年龄加速。

要点

  • 慢性HBV患者表观遗传年龄显著高于实际年龄(P < .001)。
  • HCV患者年龄加速与肝纤维化或HIV合并感染相关(P < .05),与HCV单纯感染无关。
  • 免疫标志物定义的年龄加速与DNA甲基化一致(相关系数=.59,P=.0025)。

核心结论

  • 慢性病毒性肝炎患者存在加速的表观遗传衰老。
  • 免疫标志物可定义生物学年龄,并有望评估治疗干预对年龄加速的影响。

研究设计与样本

  • 研究纳入慢性HBV感染患者51例和慢性HCV感染患者63例,伴或不伴HIV合并感染。
  • 年龄加速通过表观遗传年龄(Horvath时钟)与实际年龄的差值测量。
  • 免疫标志物模型使用弹性网络回归选择免疫标志物及其权重。

主要发现

  • 慢性HBV患者(n=51)的表观遗传年龄中位数显著高于实际年龄(P < .001)。
  • 慢性HCV患者(n=63)中,年龄加速与组织学评估的肝纤维化(P < .05)或HIV合并感染(P < .05)相关,与HCV单纯感染无关。
  • 免疫标志物定义的年龄加速与DNA甲基化定义的年龄加速一致(HBV中相关系数=.59,P=.0025)。
  • HBV患者接受核苷类治疗1年与免疫标志物模型测量的年龄加速 modest 减少相关(-.65年,P=.018)。

临床怎么用

  • 对于慢性HBV或HCV患者,可考虑评估表观遗传年龄加速以识别衰老相关风险。
  • 免疫标志物模型可作为评估治疗干预对生物学年龄影响的潜在工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several chronic diseases accelerate biological aging. We investigated age acceleration and the association between peripheral blood DNA methylation (DNAm) and immune cell markers in patients chronically infected with the hepatitis B virus (HBV) or the hepatitis C virus (HCV) with and without human immunodeficiency virus (HIV) co-infection. METHODS: Age acceleration was measured as the difference between epigenetic age (Horvath clock) and chronological age. The immune marker model of age acceleration was developed using Elastic Net regression to select both the immune markers and their associated weights in the final linear model. RESULTS: Patients with chronic HBV (n = 51) had a significantly higher median epigenetic age compared to chronological age (age accelerated) (P < .001). In patients with chronic HCV infection (n = 63), age acceleration was associated with liver fibrosis as assessed by histology (P < .05), or presence of HIV co-infection (P < .05), but not HCV mono-infection. Age acceleration defined by immune markers was concordant with age acceleration by DNA methylation (correlation coefficient = .59 in HBV; P = .0025). One-year treatment of HBV patients with nucleoside therapy was associated with a modest reduction in age acceleration, as measured using the immune marker model (-.65 years, P = .018). CONCLUSION: Our findings suggest that patients with chronic viral hepatitis have accelerated epigenetic aging, that immune markers define biological age, and have the potential to assess the effects of therapeutic intervention on age acceleration.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gindin Y, Gaggar A, Lok AS, et al. DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic Hepatitis B Virus or Hepatitis C Virus, with or without Human Immunodeficienct Virus Co-infection. Clin Infect Dis. 2021. PMID: 32915202. doi:10.1093/cid/ciaa1371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。